As shown in previous studies, there is an increased incidence of mortality in CKD patients with cardiovascular abnormalities, our primary goal should be to curb this incidence using tools like cardiac biomarkers. In a cohort study by Oka et al. involving 2,998 patients with non-dialysis CKD, monitoring BNP levels was linked to a reduced risk of kidney replacement therapy, acute kidney injury, and hospitalisation due to heart failure. These findings suggest that BNP monitoring can help physicians manage fluid levels more effectively, potentially leading to better kidney outcomes. The gene discussed is NPPB; the disease is chronic kidney disease.